Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: structure-activity relationships

Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. Method...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 66; no. 11; pp. 2543 - 2555
Main Authors Tandon, Rashmi, Ponnan, Prija, Aggarwal, Neha, Pathak, Rakesh, Baghel, Anil S., Gupta, Garima, Arya, Anu, Nath, Mahendra, Parmar, Virinder S., Raj, Hanumantharao G., Prasad, Ashok K., Bose, Mridula
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.11.2011
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. Methods A series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action. Results 7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action. Conclusions The present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
AbstractList OBJECTIVESThe objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent.METHODSA series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action.RESULTS7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action.CONCLUSIONSThe present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. Methods A series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action. Results 7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action. Conclusions The present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. A series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action. 7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action. The present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. A series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action. 7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action. The present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in combination with isoniazid, rifampicin, streptomycin or ethambutol, and to decipher the mode of action of the most effective agent. Methods A series of amino and acyl amino coumarins were synthesized and screened for activity against the Mycobacterium tuberculosis H37Rv strain. These compounds were further evaluated by standard assay procedures to determine their MBCs, fractional inhibitory concentration index values and cytotoxicities. The MICs for a susceptible and a multidrug-resistant clinical isolate of M. tuberculosis were also determined. Electron and fluorescence microscopy of the test compound-treated mycobacterial samples were also carried out in an attempt to find out the target of action. Results 7-Amino-4-methylcoumarin (7-amino-4-methyl-2H-chromen-2-one; NA5) displayed the lowest MIC of 1 mg/L against not only H37Rv but also the susceptible as well as the multidrug-resistant clinical isolates. Certain acyl amino coumarins were also found to inhibit the aforementioned strains and isolates with MICs in the range of 1.0-3.5 mg/L. They were also found to act in synergy with isoniazid/rifampicin. Electron microscopy revealed the cell-wall-attacking characteristic of these compounds, while fluorescence microscopy indicated that mycolic acid might be the target of action. Conclusions The present study clearly demonstrated the in vitro antitubercular potential of the novel drug candidate NA5. Further studies are warranted to establish the in vivo efficacy and therapeutic potential of NA5.
Author Raj, Hanumantharao G.
Gupta, Garima
Arya, Anu
Aggarwal, Neha
Parmar, Virinder S.
Pathak, Rakesh
Ponnan, Prija
Bose, Mridula
Tandon, Rashmi
Prasad, Ashok K.
Nath, Mahendra
Baghel, Anil S.
Author_xml – sequence: 1
  givenname: Rashmi
  surname: Tandon
  fullname: Tandon, Rashmi
  organization: 1 Department of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 2
  givenname: Prija
  surname: Ponnan
  fullname: Ponnan, Prija
  organization: 1 Department of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 3
  givenname: Neha
  surname: Aggarwal
  fullname: Aggarwal, Neha
  organization: 2 Department of Chemistry, University of Delhi, Delhi 110 007, India
– sequence: 4
  givenname: Rakesh
  surname: Pathak
  fullname: Pathak, Rakesh
  organization: 3 Department of Microbiology, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 5
  givenname: Anil S.
  surname: Baghel
  fullname: Baghel, Anil S.
  organization: 1 Department of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 6
  givenname: Garima
  surname: Gupta
  fullname: Gupta, Garima
  organization: 1 Department of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 7
  givenname: Anu
  surname: Arya
  fullname: Arya, Anu
  organization: 2 Department of Chemistry, University of Delhi, Delhi 110 007, India
– sequence: 8
  givenname: Mahendra
  surname: Nath
  fullname: Nath, Mahendra
  organization: 2 Department of Chemistry, University of Delhi, Delhi 110 007, India
– sequence: 9
  givenname: Virinder S.
  surname: Parmar
  fullname: Parmar, Virinder S.
  organization: 2 Department of Chemistry, University of Delhi, Delhi 110 007, India
– sequence: 10
  givenname: Hanumantharao G.
  surname: Raj
  fullname: Raj, Hanumantharao G.
  organization: 1 Department of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
– sequence: 11
  givenname: Ashok K.
  surname: Prasad
  fullname: Prasad, Ashok K.
  organization: 2 Department of Chemistry, University of Delhi, Delhi 110 007, India
– sequence: 12
  givenname: Mridula
  surname: Bose
  fullname: Bose, Mridula
  email: mridulabose@hotmail.com
  organization: 3 Department of Microbiology, V. P. Chest Institute, University of Delhi, Delhi 110 007, India
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24628768$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21917615$$D View this record in MEDLINE/PubMed
BookMark eNqF0V2LEzEUBuAgK2539cYfIIMggjDuySSZSbyT4hcseKPXw2l6xqZOk5oPof56U1td8EKvQuDhPcl5r9iFD54Ye8zhJQcjbrZob9Zfo1DqHltw2UPbgeEXbAECVDtIJS7ZVUpbAOhVrx-wy44bPvRcLVhabjCizRTdD8wu-CZMzdDizvnQynZHeXOYbSg7jM43mBr0DU0T2ey-U71kl8uKoi0zxga_kM-vmpRjsblEavHIXD40keZf6Wnj9ukhuz_hnOjR-bxmn9---bR8395-fPdh-fq2tRJUbo2YOoMIYhpAkNBKW7PSdiXBcqv1MFlQyCsi2XHL10II1BJhDbYnIbm4Zs9PufsYvhVKedy5ZGme0VMoaTQdaOilMv-V2mgFnYGjfPqX3IYSff3GaOp-67Ogr-jFCdkYUoo0jfvo6gYPI4fxWNlYKxtPlVX85JxYVjta_6G_O6rg2RlgsjhPEb116c7JvtNDr-9cKPt_DfwJj-Wusg
CODEN JACHDX
CitedBy_id crossref_primary_10_1038_s41598_020_80227_y
crossref_primary_10_1016_j_apjtm_2016_01_021
crossref_primary_10_1016_j_bmcl_2013_09_035
crossref_primary_10_1016_j_tube_2015_01_005
crossref_primary_10_1007_s11094_020_02134_w
crossref_primary_10_1016_j_apjtb_2016_08_007
crossref_primary_10_1002_ptr_5890
crossref_primary_10_1186_s12866_020_01912_6
crossref_primary_10_1016_j_tube_2018_08_004
crossref_primary_10_1007_s00253_016_7660_z
crossref_primary_10_1038_s41598_017_04108_7
crossref_primary_10_1080_21501203_2022_2027537
crossref_primary_10_1016_j_funbio_2023_01_008
crossref_primary_10_1016_j_pupt_2017_08_003
crossref_primary_10_1002_jhet_1917
crossref_primary_10_3390_M1830
crossref_primary_10_1016_j_ejmech_2018_02_067
crossref_primary_10_1073_pnas_1302114110
crossref_primary_10_1586_eri_12_91
crossref_primary_10_1089_mdr_2019_0191
crossref_primary_10_5812_jjm_129482
crossref_primary_10_1155_2013_373516
crossref_primary_10_1155_2017_7185649
crossref_primary_10_1039_C7RA05051H
crossref_primary_10_1016_j_molstruc_2023_136026
crossref_primary_10_1016_j_ijantimicag_2019_02_013
Cites_doi 10.1016/j.drudis.2008.09.004
10.1080/14756360400002015
10.1093/jac/dkn307
10.1016/j.jep.2004.03.006
10.1093/jac/dkl227
10.1038/31159
10.1093/jac/dkg301
10.1021/jm020266b
10.1378/chest.99.2.465
10.1093/jac/dkf075
10.1001/jama.282.7.677
10.1128/AAC.01601-09
10.1111/j.1747-0285.2010.00997.x
10.1073/pnas.0608654104
10.1128/JCM.36.2.362-366.1998
10.1016/0022-1759(83)90303-4
10.1111/j.1574-6968.1994.tb07194.x
10.1159/000226425
10.1021/cr60274a001
10.1021/jo00404a028
10.1128/AAC.2.1.29
10.1128/AAC.4.1.62
10.1055/s-2003-45109
10.1164/rccm.200206-626OC
10.1097/01.mcp.0000219266.27439.52
10.1021/jm010137f
10.1099/00221287-63-1-41
10.1128/AAC.40.11.2459
10.1038/nrmicro2236
10.1016/S1359-6446(05)03626-3
10.1093/jac/40.1.27
10.1001/archinte.163.9.1009
10.1021/np049706n
10.1164/ajrccm.163.5.2007122
10.1001/jama.1995.03520270054031
ContentType Journal Article
Copyright The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011
2015 INIST-CNRS
Copyright Oxford Publishing Limited(England) Nov 2011
Copyright_xml – notice: The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011
– notice: 2015 INIST-CNRS
– notice: Copyright Oxford Publishing Limited(England) Nov 2011
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
DOI 10.1093/jac/dkr355
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Nursing & Allied Health Premium
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Engineering Research Database
MEDLINE
Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 2555
ExternalDocumentID 2492001301
10_1093_jac_dkr355
21917615
24628768
10.1093/jac/dkr355
Genre Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6.Y
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABQTQ
ABSAR
ABSMQ
ABWST
ABXVV
ABZBJ
ACCCW
ACFRR
ACGFO
ACGFS
ACIWK
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
BZKNY
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RHF
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
UCJ
VH1
W8F
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
~A~
AABJS
AABMN
AAESY
AAIYJ
AANRK
ABPTK
ACIMA
ADEIU
ADORX
ADQLU
AIKOY
AIMBJ
ALXQX
ASMCH
AWCFO
AZQFJ
BGYMP
BYORX
CASEJ
DPORF
DPPUQ
IQODW
OBFPC
AEHUL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
7X8
ID FETCH-LOGICAL-c405t-93f29aa03f703e3858c9b8cb40c1c887fc05a13f2e421c1d333a84a0d0c6e3413
ISSN 0305-7453
IngestDate Tue Aug 27 04:36:10 EDT 2024
Fri Aug 16 23:14:51 EDT 2024
Thu Oct 10 22:20:21 EDT 2024
Thu Sep 12 16:30:21 EDT 2024
Tue Oct 15 23:44:37 EDT 2024
Sun Oct 22 16:06:46 EDT 2023
Wed Aug 28 03:24:08 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords cell-wall attacking
synergy
amino coumarins
multidrug resistant
Coumarine derivatives
Coumarin
Cell wall
Characterization
Structure activity relation
Efficiency
Multiple resistance
Antituberculous agent
Antibacterial agent
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-93f29aa03f703e3858c9b8cb40c1c887fc05a13f2e421c1d333a84a0d0c6e3413
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 21917615
PQID 900088706
PQPubID 32192
PageCount 13
ParticipantIDs proquest_miscellaneous_920806459
proquest_miscellaneous_898502909
proquest_journals_900088706
crossref_primary_10_1093_jac_dkr355
pubmed_primary_21917615
pascalfrancis_primary_24628768
oup_primary_10_1093_jac_dkr355
PublicationCentury 2000
PublicationDate 2011-11-01
PublicationDateYYYYMMDD 2011-11-01
PublicationDate_xml – month: 11
  year: 2011
  text: 2011-11-01
  day: 01
PublicationDecade 2010
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2011
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References WHO ( key 20170425171238_DKR355C3)
Franzblau ( key 20170425171238_DKR355C19) 1998; 36
Weser ( key 20170425171238_DKR355C26) 1953; 42
Reddy ( key 20170425171238_DKR355C39) 2010; 54
Yee ( key 20170425171238_DKR355C41) 2003; 167
Winder ( key 20170425171238_DKR355C28) 1970; 63
O'Brien ( key 20170425171238_DKR355C11) 2001; 163
Appendino ( key 20170425171238_DKR355C48) 2004; 67
Leo ( key 20170425171238_DKR355C47) 1971; 71
Kone ( key 20170425171238_DKR355C22) 2004; 93
Zhang ( key 20170425171238_DKR355C14) 2006; 11
Kubinyi ( key 20170425171238_DKR355C46) 1979; 34
Barry ( key 20170425171238_DKR355C10) 2009; 7
White ( key 20170425171238_DKR355C23) 2002; 50
Cheng ( key 20170425171238_DKR355C31) 2003; 46
Jarliera ( key 20170425171238_DKR355C12) 1994; 123
Hansch ( key 20170425171238_DKR355C35) 1979
Chen ( key 20170425171238_DKR355C38) 2006; 58
Takayama ( key 20170425171238_DKR355C29) 1972; 2
Corbett ( key 20170425171238_DKR355C8) 2003; 163
key 20170425171238_DKR355C17
Matsumoto ( key 20170425171238_DKR355C40) 2006; 11
Mosmann ( key 20170425171238_DKR355C30) 1983; 65
Ho ( key 20170425171238_DKR355C21) 1997; 40
Bhatt ( key 20170425171238_DKR355C45) 2007; 104
The AIDS Control and Prevention (AIDSCAP) Project of Family Health International, The Francois-Xavier Bagnoud Center for Health and Human Rights of the Harvard School of Public Health, UNAIDS The Joint United Nation Programme on HIV/AIDS ( key 20170425171238_DKR355C4) 1996
Atkins ( key 20170425171238_DKR355C18) 1978; 43
WHO ( key 20170425171238_DKR355C1)
Koch-Weser ( key 20170425171238_DKR355C27) 1955; 71
GreenFacts ( key 20170425171238_DKR355C2)
Cole ( key 20170425171238_DKR355C13) 1998; 393
Bardou ( key 20170425171238_DKR355C44) 1996; 40
Dye ( key 20170425171238_DKR355C7) 1999; 282
Trnka ( key 20170425171238_DKR355C36) 1988
Hurdle ( key 20170425171238_DKR355C20) 2008; 62
Matoba ( key 20170425171238_DKR355C24) 1993; 34
Dixon ( key 20170425171238_DKR355C32) 2001; 44
Velayati ( key 20170425171238_DKR355C34) 2009; 55
Jain ( key 20170425171238_DKR355C37) 1996; 43
Takayama ( key 20170425171238_DKR355C33) 1973; 4
Lalloo ( key 20170425171238_DKR355C16) 2006; 12
Steele ( key 20170425171238_DKR355C42) 1991; 99
Rivers ( key 20170425171238_DKR355C15) 2008; 13
Migliori ( key 20170425171238_DKR355C9) 2002; 6
Raviglione ( key 20170425171238_DKR355C5) 1992; 70
Raviglione ( key 20170425171238_DKR355C6) 1995; 273
Yee ( key 20170425171238_DKR355C43) 2005; 20
Virsdoia ( key 20170425171238_DKR355C50) 2010; 76
Stavri ( key 20170425171238_DKR355C49) 2003; 69
Odds ( key 20170425171238_DKR355C25) 2003; 52
References_xml – volume-title: The Status and Trends of the Global HIV/AIDS Pandemic
  year: 1996
  ident: key 20170425171238_DKR355C4
  contributor:
    fullname: The AIDS Control and Prevention (AIDSCAP) Project of Family Health International, The Francois-Xavier Bagnoud Center for Health and Human Rights of the Harvard School of Public Health, UNAIDS The Joint United Nation Programme on HIV/AIDS
– volume: 13
  start-page: 1090
  year: 2008
  ident: key 20170425171238_DKR355C15
  article-title: New anti-tuberculosis drugs in clinical trials with novel mechanisms of action
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2008.09.004
  contributor:
    fullname: Rivers
– volume: 20
  start-page: 109
  year: 2005
  ident: key 20170425171238_DKR355C43
  article-title: Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs. Mycobacterium tuberculosis
  publication-title: J Enzym Inhib Med Chem
  doi: 10.1080/14756360400002015
  contributor:
    fullname: Yee
– volume: 62
  start-page: 1037
  year: 2008
  ident: key 20170425171238_DKR355C20
  article-title: A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkn307
  contributor:
    fullname: Hurdle
– volume: 34
  start-page: 248
  year: 1979
  ident: key 20170425171238_DKR355C46
  article-title: Nonlinear dependence of biological activity on hydrophobic character: the bilinear model
  publication-title: Farmaco Sci
  contributor:
    fullname: Kubinyi
– volume: 93
  start-page: 43
  year: 2004
  ident: key 20170425171238_DKR355C22
  article-title: Traditional medicine in North Cote-d'Ivoire: screening of 50 medicinal plants for antibacterial activity
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2004.03.006
  contributor:
    fullname: Kone
– volume: 58
  start-page: 332
  year: 2006
  ident: key 20170425171238_DKR355C38
  article-title: Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkl227
  contributor:
    fullname: Chen
– volume: 393
  start-page: 537
  year: 1998
  ident: key 20170425171238_DKR355C13
  article-title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
  publication-title: Nature
  doi: 10.1038/31159
  contributor:
    fullname: Cole
– volume: 52
  start-page: 1
  year: 2003
  ident: key 20170425171238_DKR355C25
  article-title: Synergy, antagonism, and what the chequerboard puts between them
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkg301
  contributor:
    fullname: Odds
– volume: 42
  start-page: 828
  year: 1953
  ident: key 20170425171238_DKR355C26
  article-title: Studies on the metabolic significance of acid-fastness of tubercle bacilli
  publication-title: J Lab Clin Med
  contributor:
    fullname: Weser
– volume: 46
  start-page: 3572
  year: 2003
  ident: key 20170425171238_DKR355C31
  article-title: Prediction of aqueous solubility of a diverse set of compounds using quantitative structure–property relationships
  publication-title: J Med Chem
  doi: 10.1021/jm020266b
  contributor:
    fullname: Cheng
– volume: 99
  start-page: 465
  year: 1991
  ident: key 20170425171238_DKR355C42
  article-title: Toxic hepatitis with isoniazid and rifampin. A meta-analysis
  publication-title: Chest
  doi: 10.1378/chest.99.2.465
  contributor:
    fullname: Steele
– volume-title: Substituent Constants for Correlation Analysis in Chemistry and Biology
  year: 1979
  ident: key 20170425171238_DKR355C35
  contributor:
    fullname: Hansch
– volume: 50
  start-page: 111
  year: 2002
  ident: key 20170425171238_DKR355C23
  article-title: 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkf075
  contributor:
    fullname: White
– volume: 282
  start-page: 677
  year: 1999
  ident: key 20170425171238_DKR355C7
  article-title: Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country
  publication-title: JAMA
  doi: 10.1001/jama.282.7.677
  contributor:
    fullname: Dye
– volume: 54
  start-page: 2840
  year: 2010
  ident: key 20170425171238_DKR355C39
  article-title: In vitro interactions between new antitubercular drug candidates SQ109 and TMC207
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01601-09
  contributor:
    fullname: Reddy
– volume-title: Tuberculosis Fact Sheet No. 104
  ident: key 20170425171238_DKR355C1
  contributor:
    fullname: WHO
– volume: 76
  start-page: 412
  year: 2010
  ident: key 20170425171238_DKR355C50
  article-title: Screening for in-vitro antimycobacterial activity and 3-D QSAR study of 4-(arylamino)coumarin derivatives
  publication-title: Chem Biol Drug Des
  doi: 10.1111/j.1747-0285.2010.00997.x
  contributor:
    fullname: Virsdoia
– volume: 104
  start-page: 5157
  year: 2007
  ident: key 20170425171238_DKR355C45
  article-title: Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0608654104
  contributor:
    fullname: Bhatt
– volume-title: WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide
  ident: key 20170425171238_DKR355C3
  contributor:
    fullname: WHO
– volume: 36
  start-page: 362
  year: 1998
  ident: key 20170425171238_DKR355C19
  article-title: Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.36.2.362-366.1998
  contributor:
    fullname: Franzblau
– volume: 65
  start-page: 55
  year: 1983
  ident: key 20170425171238_DKR355C30
  article-title: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(83)90303-4
  contributor:
    fullname: Mosmann
– volume: 123
  start-page: 11
  year: 1994
  ident: key 20170425171238_DKR355C12
  article-title: Mycobacterial cell wall: structure and role in natural resistance to antibiotics
  publication-title: FEMS Microbiol Lett
  doi: 10.1111/j.1574-6968.1994.tb07194.x
  contributor:
    fullname: Jarliera
– ident: key 20170425171238_DKR355C17
– volume: 55
  start-page: 303
  year: 2009
  ident: key 20170425171238_DKR355C34
  article-title: Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy
  publication-title: Chemotherapy
  doi: 10.1159/000226425
  contributor:
    fullname: Velayati
– volume: 11
  start-page: 2131
  year: 2006
  ident: key 20170425171238_DKR355C40
  article-title: OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
  publication-title: PLoS Med
  contributor:
    fullname: Matsumoto
– volume: 71
  start-page: 525
  year: 1971
  ident: key 20170425171238_DKR355C47
  article-title: Partition coefficients and their uses
  publication-title: Chem Rev
  doi: 10.1021/cr60274a001
  contributor:
    fullname: Leo
– volume: 43
  start-page: 1975
  year: 1978
  ident: key 20170425171238_DKR355C18
  article-title: Substituted coumarins and aza coumarins. Synthesis and fluorescent properties
  publication-title: J Org Chem
  doi: 10.1021/jo00404a028
  contributor:
    fullname: Atkins
– volume-title: Scientific Facts on Drug-Resistant Tuberculosis
  ident: key 20170425171238_DKR355C2
  contributor:
    fullname: GreenFacts
– volume: 2
  start-page: 29
  year: 1972
  ident: key 20170425171238_DKR355C29
  article-title: Effect of isoniazid on the in-vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.2.1.29
  contributor:
    fullname: Takayama
– volume: 4
  start-page: 62
  year: 1973
  ident: key 20170425171238_DKR355C33
  article-title: Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.4.1.62
  contributor:
    fullname: Takayama
– volume: 71
  start-page: 556
  year: 1955
  ident: key 20170425171238_DKR355C27
  article-title: The influence of isoniazid and streptomycin on acid-fastness, tetrazolium reduction, growth and survival of tubercle bacilli
  publication-title: Am Rev Tuberc
  contributor:
    fullname: Koch-Weser
– volume: 69
  start-page: 956
  year: 2003
  ident: key 20170425171238_DKR355C49
  article-title: Pangelin, an antimycobacterial coumarin from Ducrosia anethifolia
  publication-title: Planta Med
  doi: 10.1055/s-2003-45109
  contributor:
    fullname: Stavri
– volume: 167
  start-page: 1472
  year: 2003
  ident: key 20170425171238_DKR355C41
  article-title: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200206-626OC
  contributor:
    fullname: Yee
– start-page: 31
  volume-title: Anti-tuberculosis Drugs
  year: 1988
  ident: key 20170425171238_DKR355C36
  article-title: Experimental evaluation of efficacy
  contributor:
    fullname: Trnka
– volume: 6
  start-page: 858
  year: 2002
  ident: key 20170425171238_DKR355C9
  article-title: Frequency of recurrence among MDR-TB cases successfully treated with standardized short-course chemotherapy
  publication-title: Int J Tubercul Lung Dis
  contributor:
    fullname: Migliori
– volume: 12
  start-page: 179
  year: 2006
  ident: key 20170425171238_DKR355C16
  article-title: Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis
  publication-title: Curr Opin Pulm Med
  doi: 10.1097/01.mcp.0000219266.27439.52
  contributor:
    fullname: Lalloo
– volume: 44
  start-page: 3795
  year: 2001
  ident: key 20170425171238_DKR355C32
  article-title: One-dimensional molecular representations and similarity calculations: methodology and validation
  publication-title: J Med Chem
  doi: 10.1021/jm010137f
  contributor:
    fullname: Dixon
– volume: 63
  start-page: 41
  year: 1970
  ident: key 20170425171238_DKR355C28
  article-title: Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis
  publication-title: J Gen Microbiol
  doi: 10.1099/00221287-63-1-41
  contributor:
    fullname: Winder
– volume: 43
  start-page: 183
  year: 1996
  ident: key 20170425171238_DKR355C37
  article-title: In vitro activity of ofloxacin against clinical isolates of Mycobacterium tuberculosis
  publication-title: Ind J Tub
  contributor:
    fullname: Jain
– volume: 40
  start-page: 2459
  year: 1996
  ident: key 20170425171238_DKR355C44
  article-title: Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.40.11.2459
  contributor:
    fullname: Bardou
– volume: 7
  start-page: 845
  year: 2009
  ident: key 20170425171238_DKR355C10
  article-title: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro2236
  contributor:
    fullname: Barry
– volume: 11
  start-page: 21
  year: 2006
  ident: key 20170425171238_DKR355C14
  article-title: New drug candidates and therapeutic targets for tuberculosis therapy
  publication-title: Drug Discov Today
  doi: 10.1016/S1359-6446(05)03626-3
  contributor:
    fullname: Zhang
– volume: 40
  start-page: 27
  year: 1997
  ident: key 20170425171238_DKR355C21
  article-title: In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/40.1.27
  contributor:
    fullname: Ho
– volume: 163
  start-page: 1009
  year: 2003
  ident: key 20170425171238_DKR355C8
  article-title: The growing burden of tuberculosis: global trends and interactions with HIV epidemic
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.163.9.1009
  contributor:
    fullname: Corbett
– volume: 67
  start-page: 2108
  year: 2004
  ident: key 20170425171238_DKR355C48
  article-title: Antimycobacterial coumarins from the Sardinian giant fennel (Ferula communis)
  publication-title: J Nat Prod
  doi: 10.1021/np049706n
  contributor:
    fullname: Appendino
– volume: 34
  start-page: 2786
  year: 1993
  ident: key 20170425171238_DKR355C24
  article-title: Combination drug testing of Mycobacterium chelonae
  publication-title: Investig Ophthalmol Vis Sci
  contributor:
    fullname: Matoba
– volume: 70
  start-page: 515
  year: 1992
  ident: key 20170425171238_DKR355C5
  article-title: HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment
  publication-title: Bull WHO
  contributor:
    fullname: Raviglione
– volume: 163
  start-page: 1055
  year: 2001
  ident: key 20170425171238_DKR355C11
  article-title: The need for new drugs against tuberculosis: obstacles, opportunities, and next steps
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/ajrccm.163.5.2007122
  contributor:
    fullname: O'Brien
– volume: 273
  start-page: 220
  year: 1995
  ident: key 20170425171238_DKR355C6
  article-title: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic
  publication-title: JAMA
  doi: 10.1001/jama.1995.03520270054031
  contributor:
    fullname: Raviglione
SSID ssj0006568
Score 2.246958
Snippet Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and...
The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and in...
OBJECTIVESThe objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and...
Objectives The objective of the present study was to evaluate the antitubercular activity of amino and acyl amino derivatives of coumarins when used alone and...
SourceID proquest
crossref
pubmed
pascalfrancis
oup
SourceType Aggregation Database
Index Database
Publisher
StartPage 2543
SubjectTerms Antibiotics. Antiinfectious agents. Antiparasitic agents
Antitubercular Agents - pharmacology
Biological and medical sciences
Cell Wall - drug effects
Chemical compounds
Coumarins - chemistry
Coumarins - pharmacology
Cytotoxicity
Drug resistance
Drug Resistance, Multiple, Bacterial
Drug Synergism
Ethambutol - pharmacology
Gram-positive bacteria
Isoniazid - pharmacology
Medical sciences
Microbial Sensitivity Tests
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Mycolic Acids - metabolism
Pharmacology. Drug treatments
Prescription drugs
Rifampin - pharmacology
Streptomycin - pharmacology
Structure-Activity Relationship
Title Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: structure-activity relationships
URI https://www.ncbi.nlm.nih.gov/pubmed/21917615
https://www.proquest.com/docview/900088706
https://search.proquest.com/docview/898502909
https://search.proquest.com/docview/920806459
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2MwxtZ9Zd2KYKNP9erPxNpbKe3KaLswHMibOctS4maxg50wkr9-p8hWkq3Z14sJsrg8_E7Snfy73xHy3uMsYFKmFg9SYfkJS60w9EOrKzEZA5Agu6pQ-Pqmc9n3Pw-CQau13KwumSUf-PLOupL_QRXHEFdVJfsPyBqjOIC_EV98IsL4_CuMz4za8tJEfl0LJlleWL6lmkMvvvFCkaizXDWUwbWs-RuKLgSqQHeeiFIzUWFYXxNqRdl5KSxV87BqLVE2jLlRNq12hLPK3CRbyTopyZGRmNS1XebOPoKmc8hXqEaTzOzKRV43Se6V2a05Jk6HQyi_g6Zsi5EZ76nb_rE2MxbVaPPeQhHnzL2F0Hut37ERTt2sq9mMdQuWxumcza010HpO9TGNqVBw5xGg5bFugeMzHZeenrattH3zJb7oX13F0fkgukfuu10WKDrop8GaHoRxbtjI2TLvBO2daGtbAYwuinw0hQpXlNStUHbnKquYJXpCHtfo0FPtOU9JS-T75MF1TafYJ0c9LVy-OKbRug6vOqZHtLeWNF88I9XPnkYLSXd5GoWKQk6Np9FtT6MrT_tIf_UzuuVnz0n_4jw6u7Tqdh0Wx6h_ZjFPugzA9iSeIkJ9cOYsCXni29zheJZJbgfg4CThuw53Us_zIPTBTm3eESqYekH28iIXrwgNeep4vkiBc4EpOQdXdHmQQKfDJThgt8m7BoN4qlVZYs2m8GJEKtZItckhwvP7CVvImamuqtjGRLxNDhoo43rdV7FqsxsqekCbUPMWN2X1pQ1yUcyrOGRhYLvMZrunMBdzNaXk1CYvtY-s_13doWCm8frP9g_Iw_XaekP2EDnxFqPkWXK4cucfLRzKzQ
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+7-amino-4-methylcoumarin+as+an+effective+antitubercular+agent%3A+structure-activity+relationships&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Tandon%2C+Rashmi&rft.au=Ponnan%2C+Prija&rft.au=Aggarwal%2C+Neha&rft.au=Pathak%2C+Rakesh&rft.date=2011-11-01&rft.eissn=1460-2091&rft.volume=66&rft.issue=11&rft.spage=2543&rft.epage=2555&rft_id=info:doi/10.1093%2Fjac%2Fdkr355&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon